** Shares of Sichuan Kelun-Biotech Biopharmaceutical
jump 9.3% to HK$179.20, on course for the biggest one-day pct rise since March 14, if gains hold
** Stock hits the highest since April 30, on track to snap two sessions of fall
** The Chinese drug producer says its key product A400 (EP0031) for treatment of lung cancer has been cleared by the United States Food and Drug Administration (FDA) to progress into Phase 2 clinical development
** Hong Kong's healthcare index climbs 0.9%, Hang Seng Composite Index gains 0.1% while Hang Seng Index
slips 0.1%
** Stock up 72.7% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments